



Journal homepage:
<http://www.bsu.edu.eg/bsujournals/JVMR.aspx>

Online ISSN: 2357-0520

Print ISSN: 2357-0512



Original Research Article

Vaccination against some *E. coli* Serotypes Isolated from Diseased Broiler Chickens with Chronic Respiratory Disease (CRD)

Al Hussien M. Dahshan^a and Asmaa A. Mohamed^b

^a Department of Poultry Diseases, Faculty of Veterinary Medicine, Beni-Suef University Beni Suef 62511, Egypt

^b Veterinary supervisor animal production, Faculty of Agriculture, Al-Mina University

ABSTRACT

Broiler chickens are frequently infected with *Escherichia coli* (*E. coli*), which often results in disease and high economic losses. Poultry of all ages are susceptible to infections with *E. coli*, but the most affected are birds of 4-5 weeks. In our study Serotypes O₇₈ and O₁₈₇ were chosen as they were the most prevalent isolated serotypes from diseased broiler chicken with respiratory affections specially CRD, one hundred chicks of different ages, sex and breeds (cobb, native, sasso) were used in this study. The samples were collected from privately owned poultry farms at EL Mina, Fayoum, Giza and Beni-Suef governorates, all sampled chicks showed clinical signs characteristic for *E. coli* affections including respiratory distress with or without diarrhea, Swabs from internal organs of 60 diseased chicks were subjected to bacterial examination. Out of 53 oxidase negative strains, 40 *E. coli* isolates were recovered, other Enterobacteriaceae including, *Proteus vulgaris* and *Pseudomonas aeruginosa*. Out of 40 *E. coli* isolates, *E. coli* O₇₈ was the most predominant serotype isolated (23) with an incidence of 57.5 % followed by *E. coli* O₁₈₇ (12) isolates with an incidence of 30 % and *E. coli* O₁₁₅ (5) isolates at percentage of 12.5%, The pre-prepared vaccine against *E. coli* serotype O used in this study was designed vaccine as it contains an *E. coli* strain that has been genetically-modified by the deletion of the *aroA* gene responsible for the biosynthesis of amino acids in the virulent *E. coli* parent strain (The GMO is named *aroA*-PTA-5094). The *aroA* gene-deleted vaccine can trigger a protective immunity in poultry against infection and disease from wild, virulent *E. coli* bacteria found in the environment. However, because the *aroA* gene is deleted, the live vaccine bacterium becomes a-virulent and unable to form a self-sustaining population since the vaccine strain has lost the capability to synthesize the amino acids necessary for its survival. The *E. coli* vaccine dosages were calculated according to a titer of 5.0×10^6 cfu per dose, one hundred one day old chicks were divided into 5 groups each one 20chicks, group 1, control negative and groups 4 and 5 control positive for serotype O₇₈ and serotype O₁₇₈, while group 2 vaccinated at one day and challenged with *E. coli* O₇₈ at age of 25 day old, also group 3 vaccinated at 5 day old and challenged with *E. coli* O₁₇₈ at age of 25 day old, Two findings, the average lesion scores of air sacs in the groups 4 and 5, four and 3 birds died in the positive control at two days post challenge with *E. coli* O₇₈ and O₁₇₈ respectively. The birds were found

ARTICLE INFO

Article history:

Received: 11 2016

Accepted: 12 2016

Available Online: 12 2016

Keywords:

Broiler chicks, vaccination, *E. coli*

to have acute, severe septicemia and *E. coli* could be isolated from the livers. The mortality and morbidity rates of the birds vaccinated with *E. coli* aroA-live vaccine was great better significant difference from the positive control group showing no mortalities and low pathological picture. There were significant differences in the FCR among the 3 groups significantly less than those of the positive control groups; the body weight was higher in vaccinated groups. Our conclusion, vaccination improves health and FCR and ABW of broiler chicks.

* Corresponding author: Al-Hussien., M. Dahshan, Department of poultry diseases Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef 6511, Egypt. , Tel.: +201005660727.

E-mail: hussiendahshan73@vet.bsu.edu.eg

1. Introduction

Chronic respiratory disease of chickens (CRD) is a serious respiratory infection that is difficult or impossible to cure, has been complicated by fibrinous perihepatitis, pericarditis, and aerosacculitis. Pathogenic *E. coli* (APEC) infection occurs as an acute fatal septicemia or subacute pericarditis and airsacculitis, as well as perihepatitis, arthritis, and cellulitis with losses ranges from one to 30 percent, the disease can occur in any age group but usually occurs between 4 and 8 weeks of age. Salpingitis, peritonitis and hypopyon have been observed in association with the pericarditis. *Escherichia coli* were isolated from 22 of 22 birds with pericarditis. Various bacteria and other diseases are associated with Pericarditis. In most studies the common serotypes have been O1, O2, O35, and O78 (Sojika et al., 1965; Heller et al., 1977; Chansiripornchai and Sasipreeyajan, 2002). *E. coli* vaccines are an alternative way to prevent and control of *E. coli* infection due to the high frequency of resistance to antibiotics used in treatment of *E. coli* in farms, *E. coli* vaccines include an inactivated vaccine, a live attenuated vaccine and a recombinant vaccine. Effective inactivated vaccines against various serotypes, including O2:K1 and O78:K80 have been produced (Deb and Harry, 1976; Deb and Harry, 1978; Cessi, 1979). Recently, a commercial live vaccine for chickens has been developed The Poulvac® *E. coli* vaccine contains an *E. coli* strain that has been genetically-modified by the deletion of the *aroA* gene responsible for the

biosynthesis of amino acids in the virulent *E. coli* parent strain (The GMO is named *aroA*- PTA-5094). The *aroA* gene-deleted vaccine is capable of triggering a protective immunity in poultry against infection and disease from wild, virulent *E. coli* bacteria found in the environment. However, because the *aroA* gene is deleted, the live vaccine bacterium is avirulent and unable to form a self-sustaining population since the vaccine strain has lost the capability to synthesize the amino acids necessary for its survival, the *E. coli* *aroA*-live vaccine can protect against the homologous and heterologous serogroups. The objective of our study was to prove the efficacy of the *E. coli* *aroA*-live vaccine against *E. coli* serotypes O78 and O178.

2. Materials and methods

2.1. samples:

One hundred samples were collected from chicks of different ages, sex and breeds (cobb, native, sasso) from privately owned poultry farms at EL Mina, Fayoum, Giza and Beni-Suef governorates, all sampled chicks showed clinical signs characteristic for *E. coli* affections including respiratory distress with or without diarrhea, Swabs from internal organs of 50 diseased chicks were subjected to bacterial examination.

2.2. Chickens

One hundred unvaccinated apparent healthy one day old chicks were divided into 5 groups each one 20chicks. The used chicks will be floored reared and fed on a balanced commercial ration; the chickens were fed ad libitum before and during the experiments.

2.3. Bacteriological examination:

2.3.1. Isolation of bacterial agents:

The samples from internal organs (heart, liver and intestine) were collected, Using different selective and differential media including Tryptone soya broth and tetrathionate broth then incubated at 37°C for 18-24 hours plating onto (MacConkey's, , Eosin Methylene Blue, Tryptone soya agar and XLD medium) and incubated at 37 °C for 18-24 hours. 2.4. Post mortem examination

2.3.2. Morphological examination

According to **Cruickshank et al, (1975)**

2.3.3. Biochemical identification:

The pure colonies of isolates were identified biochemically according to **Quinn et al. (2002); Koneman et al. (1995) and Finegold and Martin (1982).**

2.4. Detection of virulence factors:

Congo red binding test and haemolytic activity were performed for differentiation of pathogenic and non-pathogenic bacterial isolates also for differentiation between haemolytic and non haemolytic isolates according to (**Berkhoff and Vinal, 1986**).

2.5. Serological identification of *E. coli*:

Isolates that were preliminary identified biochemically as *E.coli* were subjected to serological identification according to **Ewing (1986)**.

2.6. Vaccination and Experimental designs

2.6.1. Vaccine:

Poulvac® *E. coli* vaccine (Fort Dodge Animal Health, Iowa, USA) contains an *E. coli* strain that has been genetically-modified by the deletion of the *aroA* gene responsible for the biosynthesis of amino acids in the virulent *E. coli* parent strain (The GMO is named *aroA*- PTA-5094). Was orally administered to the chickens according to the manufacture's recommendation, The *E. coli* vaccine dosages were

calculated according to a titer of 5.0×10^6 cfu per dose.

2.6.2. Experimental designs

-Group 1 control negative group for both serotypes O78 and O178 and groups 4 and 5 kept as control positive for serotype O78 and serotype O178 respectively, while group 2 vaccinated and challenged with *E.coli* virulent O78 strain (homologous challenge), also group 3 vaccinated and challenged with *E.coli* O178 virulent strain (homologous challenge) .

-Group 2 and group 3 were vaccinated at 5 days old orally with Poulvac® *E. coli* vaccine, The *E. coli* vaccine dosages were calculated according to a titer of 5×10^6 cfu per dose.

- Before inoculation, random samples consisting of tracheal swabs were subjected bacteriological examinations which proved to be healthy and free from any pathogenic *E.coli*.

- 0.5 ml of the *E. coli* suspension, containing 3×10^8 cfu/ml of *E. coli* O78 according to McFarland standard reactions was used for intratracheal challenge at 25 days of age.

-0.5 ml of the *E. coli* suspension, containing 3×10^8 cfu/ml of *E. coli* O178 according to McFarland standard reactions was used for intratracheal challenge at 25 days of age.

- At 7 days post challenge, the total number of dead birds was noted, and all the surviving birds were necropsied and examined for the presence of grossly visible lesions of Colibacillosis.

2.6.3. Parameters evaluated

A-Morbidity and mortality rates were calculated

B-The pericardial and perihepatic lesions of colisepticemia in each bird were scored. The pericardial lesions of colisepticemia were scored according to (**Charleston et al. 1998**) as follows: 0: no visible lesions, 1: definite fibrination on the surface of the liver, 2: extensive fibrination, adhesions, liver swelling and necrosis. Chickens with severe lesions were characterized as having a pericarditis and perihepatitis scores of either 1 or 2.

C- The average body weight of the birds in each group was measured at 7 day, 14 days, 21 days, 28 days and 35 days of age.

D- A feed conversion ratio (FCR) was calculated for each group by taking the total amount of feed consumed by each group between days

3. Results

3.1. Bacteriological examination

Out of 100 cases 60 (60%) were positive with bacterial isolates, 53 positive for Enterobacteriaceae, out of 53 oxidase negative strains, 40(75.4%) *E. coli* isolates were recovered, 13(24.52%) (Table1). Other Enterobacteriaceae including *Proteus vulgaris* and *Pseudomonas aeruginosa*, *E. coli* O78 was the most predominant *E.coli* isolates, (23) out of 40 *E.coli* isolates with an incidence of 57.5 % followed by *E. coli* O187 (12) isolates with an incidence of 30 % and *E. coli* O115 (5) isolates at percentage of 12.5%(Table 2)

sacs in the groups vaccinated with *E. coli* aroA-live vaccine

each group were revealed the improvement of the pathological lesions in vaccinated groups 2 and 3 in comparison with the control positive groups. were recorded. There was a significant difference in the FCR among the 4 groups significantly less than those of the positive control groups (Table 3) and the histopathological examination of liver sections for Two chicks died in the positive control groups 4 and 5 two days post challenge with *E. coli* O78, O178 respectively. The postmortem examination were severe septicemic picture and *E. coli* reisolated from the liver. No mortality and low morbidity rates in the

in the vaccinated groups (2 and 3) with *E. coli* aroA-live vaccine. For, the average lesion scores of air

Table 1. the overall bacterial isolation from diseased chicks with respiratory signs

Bacterial isolation from chicks	Number	Percentage
Bacterial isolates /100	60	60 %
Enterobacteriaceae isolates /60	53	88.3 %
<i>E.coli</i> isolates /53	40	75.4%
Other Enterobacteriaceae / 53	13	24.5%
Negative isolation / 100	40	40 %

3.2. Experimental infection

Table 2. Serogroups of *E. coli* isolated from different organs of diseased birds

Serotype	Number / 40	Percentage
O78	23	57.5 %
O178	12	30 %
O115	5	12.5%

Table 3. Performance parameters & lesion score in E coli infected, Control and vaccinated groups.												
group	Morbidity		Mortality		Average body weight /week ±SD					FCR	Lesion score	
	NO.	%	NO	%	1 st	2 nd	3 rd	4 th	5 th		birds with Mean gross lesion score NO.	%
1(n=20)	0	0	0	0	190±48	405±77	765±125	1150±201	1770±322	1.9	0	0
2(n=20)	2	10%	0	0	180±41	400±64	751±104	1080±145	1650±297	1.7	1/2 Perihepatic lesion	50%
3(n=20)	3	15%	0	0	183±42	408±69	745±98	1120±125	1580±266	1.6	1/3 Pericardial lesion	33.3%
4(n=20)	7	35%	2/2 0	10%	187±44	208±69	390±88	645±104	860±112	2.6	5/7 extensive fibrination in liver and heart	71.4%
5(n=20)	8	40%	2/2 0	10%	180±42	210±69	375±74	675±110	900±125	2.4	7/8 extensive fibrination in liver and heart	87.5%




Figure 1.
A: apparently normal parenchyma. (Group 1)
B: focal area of necrosis infiltrated by mononuclear cells infiltration (Group 4).
C: focal area of necrosis infiltrated by mononuclear cells infiltration (Group 5).
D: slight portal tract congestion with slight leucocytic infiltration (Group 2).
E: slight portal tract congestion with slight leucocytic infiltration (Group 3).
F: leucocytic infiltration (Group 4).

4. Discussion

The majority of commercially produced poultry are known to have some *E.coli* with some strains inherently more pathogenic than others, and when mortality occur the bacteria is often implicated. Those strains causing disease, known as avian pathogenic *E.coli* (APEC), have developed adaptations enabling them to live outside the intestinal tract, leading to both localized and systemic manifestations of the disease. Most of these strains are pathogenic for poultry only and are responsible for the most common infectious bacterial disease of farmed poultry. The most common conditions include septicaemia, peritonitis airsacculitis and septicaemia complex in commercial broilers; in the current study the body performances of the chicks were evaluated in the concept of vaccination with *E. coli* aroA-live vaccine, The results revealed that the vaccine tends to prevent *E. coli* infection. The vaccinated chickens in groups 2 and 3 tended to show lower morbidity and pathological findings including fewer airsacculitis, pericarditis, perihepatitis and peritonitis than the chickens in groups 4 and 5 than the chickens in the positive control group. While the FCR was significantly different in each group,

5. Conclusion

It is concluded that PCR was the *E. coli* aroA-live vaccine tends to reduce the pathological lesions of the chickens challenged with *E. coli* serotypes O78 and O178

Acknowledgements

Great thanks for the staff of the Department of poultry diseases, Faculty of Veterinary Medicine, Beni-Suef University for the great effort during the entire practical section as well as the moral support.

References

- Berkhoff, H. A. and Vinal, A. C. (1986): Congo red medium to distinguish between invasive and non-invasive *Escherichia coli* pathogenic for poultry. *Avian Dis.*, 30(1): 117-121.
- Cessi, D. (1979). Prophylaxis of *Escherichia coli* infection in fowls with emulsified vaccines. *Clin. Vet.* 102(4): 270-278.
- Chansiripornchai, N. and Sasipreeyajan, J. (2002). Efficacy of sarafloxacin in broilers after experimental infection with *Escherichia coli*. *Vet. Res. Comm.* 26(4): 255-262.
- Charleston, B., Gate, J.J., Aitken, I.A. Stephan, B. and Froyman, R. (1998). Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against *Escherichia coli* infection in chickens. *Antimicrob. Agent Chemother.* 42(1): 83-87.
- Cruichshank, R.; Duguid, J.P.J; Marmion, B.P. and Swain, R.H.A. (1975): *Medical Microbiology* 12th ed. Velum II Churchill, living stone Edinburgh, London and New York.
- Deb, J.R. and Harry, E.G. (1976). Laboratory trials with inactivated vaccines against *Escherichia coli* (O78:K80) infection in fowls. *Res. Vet. Sci.* 20(2): 131-138.
- Deb, J.R. and Harry, E.G. (1978). Laboratory trials with inactivated vaccines against *Escherichia coli* (O2: K1) infection in fowls. *Res. Vet. Sci.* 24(3): 308-313.
- Ewing, W.H. (1986): *Identification of Enterobacteriaceae*. 4th ed. Elsevier Science., New York.
- Finegold, S.M. and Martin, W.T. (1982): *Diagnostic microbiology*. 6th ed.C.V. Mosby Company St. louis, Toronto.
- Heller, E.D. and Drabkin, N. (1977). Some characteristics of pathogenic *E. coli* strains. *Br. Vet. J.* 133(6): 572-578.
- Koneman, E.W.; Allen, S.D.; Janda, W.M.; Schreckenberger, P.C. and Winn, W.C. (1995): *Introduction to Diagnostic Microbiology*.
- Quinn, P.J.; Carter, M.E.; Markey, B.K.; Donnelly, W.J.C. and Leonard, F.C. (2002): *Veterinary Microbiology and Microbial diseases*, Great Britain by MPG, Book. 1st ed., Bodmin, Cornwall, UK.
- Sojka, W.J. (1965). *Escherichia coli* in Domestic Animals and Poultry. Commonwealth Agricultural Bureau: Farnham Royal, England.